L. Athira Krishna

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Retrieved on: 
Tuesday, January 31, 2023
Neurodegeneration, Washington State University, St. Kevin's Church, Camden Row, Dublin, Athira Pharma, University of Idaho, Doctor of Philosophy, University, Management, Research, L. Athira Krishna, Microbiology

BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.

Key Points: 
  • BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer.
  • “Kevin is a driving force behind our research at Athira.
  • He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET pathway and its potential applications for the treatment of neurodegenerative disorders,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • in Microbiology from the University of Idaho and his Ph.D. in Molecular Biosciences from Washington State University.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Athira Pharma, Inc. (NASDAQ: ATHA) and Encourages Long-Term ATHA Investors to Contact the Firm

Retrieved on: 
Tuesday, December 13, 2022
Acquisition, Disclosure, L. Athira Krishna, IPO, Doctorate, Research, Complaint, Financial adviser

PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) on behalf of the Company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) on behalf of the Company’s long-term investors.
  • The investigation seeks to determine whether the members of Athira’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with alleged corporate misconduct.
  • Athira stockholders who purchased or acquired shares of the Company’s stock in September 2020 are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.)
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Retrieved on: 
Monday, December 5, 2022
Neuroprotection, Sciatic nerve, Inflammation, Research, Communication, Nature, Security (finance), AFL, ALS, NCV, Axon, Safety, Amyotrophic lateral sclerosis, Histology, Biomarker, Athira Pharma, Doctor of Philosophy, International Symposium on Graph Drawing, Maritime Transportation Security Act of 2002, Neurodegeneration, IL-6, Human, CMAP, Plasma, Disease, Neuroinflammation, Dementia, Investment, Lewy body, COVID-19, Patient, Management, Pharmaceutical industry, L. Athira Krishna

BOTHELL, Wash., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented data highlighting the potential therapeutic benefits of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in a preclinical mouse model of amyotrophic lateral sclerosis (ALS). The findings were presented at the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND.

Key Points: 
  • The findings were presented at the Motor Neurone Disease Association’s 33rd International Symposium on ALS/MND.
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.
  • Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time

Retrieved on: 
Thursday, December 1, 2022
COVID-19, EST, Athira Pharma, Communication, Nature, Dementia, Doctor of Philosophy, R, Patient, Q&A, Disease, Security (finance), Neurodegeneration, Peripheral neuropathy, Lewy body, Research, Investment, Safety, Pharmaceutical industry, L. Athira Krishna

The presentation will be delivered by the Company's executive leadership:

Key Points: 
  • The presentation will be delivered by the Company's executive leadership:
    Mark Litton, Ph.D., President and Chief Executive Officer;
    To pre-register for the event, click here .
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.
  • Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

Retrieved on: 
Tuesday, November 29, 2022
ACT, HGF, ADAS, Athira Pharma, MET, Cognition, Brain, Biomarker, Security (finance), Peripheral neuropathy, GFAP, Pathology, Dementia, Neuroinflammation, Communication, Nature, Serum, Doctor of Philosophy, Patient, COVID-19, AFL, AD, Clinical trial, GST, Drug Quality and Security Act, Neurodegeneration, Research, Safety, Hepatocyte growth factor, Lewy body, Investment, Medical imaging, Pharmaceutical industry, L. Athira Krishna

BOTHELL, Wash., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Key Points: 
  • The late-breakingposter presentation highlights the effect of fosgonimeton treatment on biomarkers associated with neurodegeneration (NfL), neuroinflammation (GFAP, YKL-40), and Alzheimers specific protein pathologies (A 42/40 ratio and p-Tau181).
  • These additional biomarker data provide further support of the therapeutic potential of fosgonimeton in patients with mild-to-moderate Alzheimers disease, said Hans J. Moebius, M.D., Ph.D., Chief Medical Officer of Athira Pharma.
  • Furthermore, directional improvements in key biomarkers associated with Alzheimers disease pathology, A 42/40 ratio and p-Tau181, provide evidence supporting fosgonimetons potential as a disease-modifying therapy.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Retrieved on: 
Monday, November 21, 2022
ACT, COVID-19, HGF, Dementia, Communication, Nature, MET, Cognition, Brain, Patient, Hepatocyte growth factor, Biomarker, Neurodegeneration, Security (finance), Peripheral neuropathy, Lewy body, Research, Investment, Athira Pharma, Safety, Pharmaceutical industry, Medical imaging, L. Athira Krishna

The function of the HGF/MET receptor system may be impaired in the brain under conditions of neurodegeneration.

Key Points: 
  • The function of the HGF/MET receptor system may be impaired in the brain under conditions of neurodegeneration.
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimers and Parkinsons disease dementia, Dementia with Lewy bodies and neuropsychiatric indications.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, HGF, Dementia, Athira Pharma, Neurotoxin, Communication, Nature, MET, Doctor of Philosophy, Pain, Neuroprotection, Alpha-synuclein, Brain, Neurotoxicity, Patient, Society, Nerve, Hepatocyte growth factor, Neurodegeneration, Research, Diabetic neuropathy, Security (finance), Peripheral neuropathy, STZ, Rotenone, PD, Lewy body, Oxidative stress, Neuron, Investment, Safety, RATS, Pharmaceutical industry, Aroma compound, Birth control, Neuroscience, L. Athira Krishna

BOTHELL, Wash., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced data highlighting the potential therapeutic benefits of enhancing the HGF/MET neurotrophic system in preclinical models of Parkinson’s disease (PD) and diabetic neuropathy. These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.

Key Points: 
  • These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.
  • The data presented at Neuroscience 2022 show that fosgonimeton (ATH-1017) promotes neuroprotection, reduces alpha-synuclein aggregation in vitro, and improves motor performance in animal models of Parkinsons disease.
  • An oral nanosymposium presentation highlighted the neuroprotective effects of fosgonimeton against neuronal damage and motor deficits in preclinical models of Parkinsons disease.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

Athira Pharma to Present at Stifel 2022 Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
Investor, GLOBE, Webcast, EST, Lewy body, Dementia, NASDAQ, Athira Pharma, Conference, L. Athira Krishna, Pharmaceutical industry, Facebook

BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athiras management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City.

Key Points: 
  • BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athiras management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City.
  • Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.
  • A live webcast of the fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-in... .
  • Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

Retrieved on: 
Monday, November 7, 2022
Molecule, ACT, Private Securities Litigation Reform Act, Nerve, Research, Investment, GLOBE, Lewy body, Safety, Securities Exchange Act of 1934, Society, Athira Pharma, COVID-19, Nature, Securities Act of 1933, Diabetic neuropathy, Dementia, San Diego Convention Center, U.S. Securities and Exchange Commission, HGF, Forward-looking statement, NASDAQ, Cognition, Security (finance), Hepatocyte growth factor, Patient, Pharmaceutical industry, Facebook, Neuroscience, L. Athira Krishna

Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.

Key Points: 
  • Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.
  • Athira is currently advancing its pipeline therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimers and Parkinsons disease dementia, Dementia with Lewy bodies and neuropsychiatric indications.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.
  • Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis

Retrieved on: 
Monday, October 17, 2022
ACT, Lewy body, National Institute, LinkedIn, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Doctor of Philosophy, Communication, MET, Risk, LIFT, Investor, Review, Population, Hope, Cognition, Particle-size distribution, NASDAQ, HGF, Hepatocyte growth factor, Patient, Securities Exchange Act of 1934, Research, Twitter, Neuroprotection, Instagram, Security (finance), Dementia, Investment, Securities Act of 1933, Private Securities Litigation Reform Act, National, Nature, Athira Pharma, Safety, AFL, ADAS, AD, GLOBE, Brain, Forward-looking statement, COVID-19, Lists of diseases, Alzheimer's disease, Neurodegeneration, Pharmaceutical industry, Medical imaging, Facebook, L. Athira Krishna, Company

BOTHELL, Wash., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD). The committee also determined that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 patients without background therapy (acetylcholinesterase inhibitors), the study will be well powered for the primary endpoint given the preliminary effect size observed. The primary endpoint of LIFT-AD is the Global Statistical Test, an unweighted composite score comprising measures of cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog11]) and function (Alzheimer’s Disease Cooperative Study-Activities of Daily Living [ADCS-ADL23]).

Key Points: 
  • Guided by these results, the Company proactively amended LIFT-AD to focus on patients not on background therapy.
  • This analysis supports the potential clinical benefits of fosgonimeton treatment and underscores the rationale for continued development of this promising new therapy.
  • The ACT-AD study suggested these benefits, and the results of the LIFT-AD interim analysis corroborate those findings, added Dr. Litton.
  • LIFT-AD is a randomized, double-blind, placebo-controlled, parallel-group study of fosgonimeton for patients with mild-to-moderate Alzheimers disease.